Soren Acquisition Corp. Announces the Pricing of $220,000,000 Initial Public Offering

Rhea-AI Summary

Soren Acquisition Corp (NASDAQ:SORN) priced an initial public offering of 22,000,000 units at $10.00 per unit, representing gross proceeds of $220,000,000, with trading of units expected to begin on January 7, 2026 under the ticker SORNU.

Each unit includes one Class A ordinary share and one-third of a redeemable warrant; whole warrants will trade separately as SORNW and will entitle holders to buy one share at $11.50 per share. The offering is expected to close on January 8, 2026 and the underwriters have a 45-day over-allotment option to purchase up to 3,300,000 additional units.

The company is a blank check vehicle focused on healthcare business combinations and named its management and board, with BTIG acting as sole book-running manager.

Positive

• Offering size of $220,000,000 from 22,000,000 units
• Nasdaq listing expected to begin on January 7, 2026 (SORNU)
• Focused deal mandate on the healthcare industry

Negative

• Company is a blank check vehicle with no operating business
• Potential dilution from over-allotment option of 3,300,000 units
• Warrants allow purchase at $11.50, creating future share dilution

Miami, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Soren Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading tomorrow, January 7, 2026, under the ticker symbol “SORNU.” Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “SORN” and “SORNW,” respectively. The offering is expected to close on January 8, 2026, subject to customary closing conditions. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,300,000 units at the initial public offering price to cover over-allotments, if any.

The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution but is focused on completing a business combination with an attractive target business within the healthcare industry.

The Company’s management team is led by Arghavan Di Rezze, its Chief Executive Officer, and Jamie Weber, its Chief Financial Officer, who are both members of the Board of Directors of the Company (the “Board”). In addition, the Board includes Marc Mazur, Charles N. Khan III and Spencer Gerrol. Peter Ondishin and Nicholas Shekerdemian serve as Advisors to the Company.

BTIG, LLC is acting as sole book-running manager for the offering. Reed Smith LLP is serving as legal counsel to the Company and Walkers (Cayman) LLP is serving as Cayman Island counsel to the Company. Ellenoff Grossman & Schole LLP is serving as legal counsel to the underwriters.

The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from BTIG, LLC, 65 East 55th Street, New York, New York 10022, or by email at ProspectusDelivery@btig.com or by accessing the SEC’s website, www.sec.gov.

A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on January 6, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds will be used as indicated.

Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contacts

Soren Acquisition Corp.
Arghavan Di Rezze, Chief Executive Officer
apd@direzzefamilyoffice.com

FAQ

When will Soren Acquisition Corp (SORN) begin trading on Nasdaq?

Units are expected to begin trading on January 7, 2026 under the ticker SORNU.

How large is the Soren Acquisition Corp initial public offering for SORN?

The IPO is 22,000,000 units at $10.00 per unit, totaling $220,000,000 in gross proceeds.

What does each Soren Acquisition Corp unit include and what is the warrant price?

Each unit includes one Class A ordinary share and one-third of a warrant; whole warrants exercise at $11.50 per share.

When is the Soren Acquisition Corp offering expected to close?

The offering is expected to close on January 8, 2026, subject to customary closing conditions.

Does Soren Acquisition Corp have an over-allotment option and how large is it?

Underwriters have a 45-day option to buy up to 3,300,000 additional units to cover over-allotments.

What is Soren Acquisition Corp's acquisition focus and management leadership?

The company is a blank check vehicle focused on healthcare deals; management includes CEO Arghavan Di Rezze and CFO Jamie Weber.